).
Biomechanical imbalance, trauma, and age-related degeneration often lead to chondral lesions which may lead to overt osteoarthritis over time. Such cartilage pathology is frequently accompanied by persistent pain and loss of normal joint function. As a result, patients who suffer from biologically active articular cartilage lesions are often unable to function in both high level activities and exhibit compromised activities of daily living. The limited potential for self-regeneration of hyaline cartilage has led to the emergence of new technologies to solve this difficult clinical problem. In the event that the chondral lesion remains superficial to the subchondral bone, repair relies on the proliferation of surrounding cells and cells within the synovium as lesions are not exposed to the cellular and protein components of circulating blood. Lesions that include the subchondral bone and expose the marrow cavity rely on components therein for regeneration and repair. Cartilage synthesized without exogenous intervention usually resembles type 1 fibrous cartilage with inferior biomechanical properties when compared with native, hyaline cartilage replete with type 2 collagen.
1
Treatment of arthritis and chondral lesions includes alleviation of pain and return of function through pharmacologic intervention and/or attempts at cartilage reparative, restorative and reconstructive options.
2 Systemic pharmacologic treatments for degenerative arthritis aim to reduce inflammation and decrease associated pain. Topical treatments include nonsteroidal antiinflammatories such as diclofenac gels that isolate the pathologic joint localizing treatment and decreasing the possibility of systemic side effects. Traditional injectables such as cortisone injections and viscosupplementation have been found to decrease pain for short and medium time periods. Corticosteroids have been shown to provide a 30 to 50% decrease in pain which is most evident in the first 4 weeks after treatment. 3 Viscosupplementation with various formulations and molecular weights of hyaluronic acid has been shown to impart similar, but longer lasting results.
4
It is our purpose to discuss the nontraditional and innovative nonsurgical treatments for articular cartilage pathology. Weight loss, physical therapy, oral antiinflammatories, and corticosteroids are, at present, the standard of care for conservative treatment modalities for arthritis. The use of biologic injectables such as growth factors, platelet rich plasma (PRP), autologous conditioned plasma (ACS Q1 Q1 Q1 ), and stem cell therapy are currently under investigation and will be the present focus. Although the clinical evidence supporting the use of these modalities is sparse, their potential is clear as is the need for their continued development.
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Abstract
Biomechanical imbalance, trauma, and age-related degeneration often lead to chondral lesions which may lead to overt osteoarthritis over time. Such cartilage pathology is frequently accompanied by persistent pain and loss of normal joint function. As a result, patients who suffer from biologically active articular cartilage lesions are often unable to function in both high level activities and exhibit compromised activities of daily living. The limited potential for self-regeneration of hyaline cartilage has led to the emergence of new technologies to solve this difficult clinical problem. Treatment of arthritis and chondral lesions includes alleviation of pain and return of function through pharmacologic intervention and/or attempts at cartilage reparative, restorative and reconstructive options.
Growth Factors and Cytokines
Osteoarthritis is largely a cytokine-driven disease process. TGF-β1 has been shown, in vitro, to stimulate the synthesis of extracellular matrix within cartilage, induce synovial proliferation, and increase mesenchymal stem cell (MSC) proliferation.
11-14 Positive effects of TGF-β1 have also been documented in cartilage defects within rabbit models.
15-19
Despite the positive effects of TGF-β1, safety concerns, specifically the presence of osteophytes and synovial fibrosis in murine and lapine studies, have limited extensive human testing. 14,20 Albeit on a smaller scale, compared with TGF-β1, TGF-β3 has been shown to stimulate extracellular matrix formation in animal models [21] [22] [23] without these adverse effects. BMP-2 is a close structural relative to both TGF-β1 and TGF-β3 and has been studied extensively in fracture care and spine surgery. The clinical success of BMP-2 in orthopedics has spurred basic science research investigating its potential effect on cartilage regeneration. In multiple studies, it has been shown in vitro to partially reverse dedifferentiated chondrocytes found in osteoarthritic models. 24 In addition, BMP-2 stimulates the synthesis and turnover of extracellular matrix, and specifically, that of proteoglycans and type II collagen. Augmentation of a microfracture model with BMP-2 has also been reported in a rabbit model. Although surgical intervention is beyond the present scope, it is valuable to note that BMP-2 may guide differentiating cells to produce more hyaline-like cartilage. [25] [26] [27] Although the effects of BMP-2 on chondrocyte metabolism seem promising, synovial thickening, fibrosis, and, in some cases, osteophytes have been shown to develop after multiple injections. 28 In addition, a recent animal study suggests temporal limitations to the use of BMP-2. 29 Although the efficacy of BMP-2 seems promising, further studies are needed to develop the most efficacious dosing, timing, and route of administration.
BMP-7/OP-1 is the most investigated member of the TGF-β superfamily for its potential to regenerate articular cartilage. Not only does BMP-7 increase ECM synthesis, it decreases the activity of catabolic cytokines such as IL-1, IL-6, IL-8, MMP-1, and MMP-7.
30 BMP-7 expression has been shown to decrease with age. Although decreased BMP-7 expression is a factor in cartilage breakdown, BMP-7 continues to have autocrine effects for both anabolism and catabolism. [31] [32] [33] [34] Finally, although basic science studies suggest a beneficial effect from the administration of BMP-7, recent basic science and clinical literature has not shown a trend between endogenous levels of BMP-7 and higher symptomatic pain relief in patients with osteoarthritis. 35 The efficacy of BMP-7 seems to be clear, however the need to develop the proper dosing, timing, and route of administration remains uncertain. Insulin-like growth factor-I has been investigated within the context of cartilage metabolism in both native and pathologic states.
30,36-39 IGF-1 has been shown to increase the anabolic response and decrease catabolism. 40 In contrast to evidence found in BMP-7, IGF-1 shows a decreased responsiveness in aging and osteoarthritic cartilage. 41, 42 Although IGF-1 may not be a viable option alone, it may offer a synergistic effect in conjunction with other growth factors.
36
Further studies are necessary to determine the optimal combination of growth factors. Recent evidence suggests that platelet-derived growth factor (PDGF) has a possible place in cartilage repair based on its role in wound healing and stimulation of ECM proliferation in bone growth. [43] [44] [45] [46] Multiple animal studies have
shown that PDGF has an excellent safety profile when used in isolation. PDGF has had an increasingly prominent role in research and media as in vivo use of PDGF remains largely within the context of PRP. PRP has been used successfully in various clinical situations and has drawn national attention as it has shown promising results for tendon healing.
Blood-Derived Products
Although growth factors show promise, they must be carefully synthesized and stored and are thus very expensive to produce. As evidenced above, they may also have a synergistic effect and would thus require varied concentrations of multiple growth factors; a practice that is not sanctioned by the American Food and Drug Administration. Thus, there has been a recent resurgence in interest in the use of the body's own combination of growth factors and cytokines using autologous blood as a medium from which to extract growth factor and cytokine-containing components such as platelets.
Autologous Conditioned Plasma
Autologous conditioned serum (ACS) was developed in the mid-1990s and marketed under the name Orthokine (Arthrex, Inc., Naples, FL). It has been reported to not only be beneficial in the treatment of osteoarthritis, but also be beneficial in rheumatoid arthritis, spinal disorders, and muscle injuries in humans. [47] [48] [49] [50] [51] To prepare an ACS injection, human whole blood from the patient is incubated with
The Journal of Knee Surgery Vol. 00 No. 00/2012 medical-grade glass beads or spheres, exposed to chromium sulfate, and placed into a centrifuge to separate into the plasma with platelets. 48 ACS is believed to be effective through its increased concentrations of cytokines and growth factors. Multiple studies have shown that the expression of IL-4, IL-10, IL-1Ra (receptor antagonist), fibroblastic growth factor-1, hepatocyte growth factor, and TGF-β1 are increased in human ACS. While there is an increase in these antiinflammatory agents, there is no increase in proinflammatory cytokines-like IL-1β or TNF-α.
47
In particular, IL-1Ra expression has been shown to increase as much as 140-fold in ACS. IL-1Ra is a competitive receptor antagonist of IL-1, a proinflammatory cytokine that triggers the destruction of hyaline cartilage and its matrix.
48
Thus IL-1Ra may play a role in the clinical improvement of osteoarthritis patients injected with ACS. IL-1 has also been identified as being the major mediator of cartilage loss in osteoarthritis. Currently, it is not clear if all biologically active IL-1 receptors need to be blocked to have a significant impact on treating conditions such as osteoarthritis, however, it is known that other antiinflammatory cytokines that are expressed in ACS also affect IL-1 receptor signaling. 48 In gene therapy studies, it was found that IL-1Ra decreases synovial effusion, gross articular cartilage erosion, and synovial membrane vascularity as compared with placebo-treated joints.
47
To induce the de novo production of IL-1Ra, aspirated venous blood is incubated with borosilicate glass spheres in a syringe. The antiinflammatory cytokines, which are produced by peripheral blood leukocytes, accumulate and are recovered within the serum. The cytokine concentrations do vary between individual samples and their synergistic action contributes to the effects. 48 After centrifugation, ACS can be injected into the osteoarthritic area in a series of six intraarticular injections twice a week for 3 weeks.
47,52
Platelet Rich Plasma
The contemporary definition of PRP is a sample of plasma with a 2-fold or more increase in platelet concentration or greater than 1.1 Â 10 6 platelets/μL. 53 Presently, several different manufacturers have developed systems for PRP preparation for augmentation or as primary orthopaedic treatments. 54 It is important to understand that preparations differ across manufacturers in final platelet count, presence of leukocytes and number of centrifugations for preparation. The concept of PRP as a possible treatment for osteoarthritis derives from the platelet's role in wound healing 55 as platelets contain many of the cytokines and growth factors delineated above. In addition, platelets contain approximately another 1500 proteins, some of which modulate the inflammatory response inherent in degenerative joint disease as well as the attraction of fibroblasts and stem cells to the site of injury.
56,57
The use of PRP and its reported clinical success in treating various tendon pathologies throughout the body has led to increased interest in its potential role in cartilage repair. The use of PRP as treatment for articular cartilage repair is new, and thus there is sparse data on the clinical outcomes of its use. In the laboratory, injected PRP has been shown to increase production of chondrocytes and MSCs leading to increased proliferation and synthesis of extracellular matrix, collagen II, and proteoglycans. 58, 59 In animal models, damaged cartilage treated with PRP also demonstrated higher degree of degeneration when compared with control. In a recent trial of hyaluronic acid versus PRP for the treatment of osteoarthritis, Kon et al 60 compares the two treatment modalities over a 6-month time period to evaluate patientreported outcomes. The study concludes that 3 weekly injections of autologous PRP, when compared with a series of three HA injections, show more and longer efficacy in mitigating the symptoms of osteoarthritis. They also conclude that younger, more active patients with presumably a lesser degree of cartilage degeneration, improve to a higher degree with PRP injections as compared with HA. These results are the most promising to date. However a randomized control trial, with more objective outcomes is needed to shed more definitive light on PRP as a treatment for cartilage degeneration. 60 A recent 24-month follow-up to has recently been published that suggest a tapering decrease in pain and the increase in function found in the short term by the time patients reach 24 months.
61

Stem Cell Therapy
Stem cell therapy serves as another possible method of treatment of articular cartilage defects. Not only do MSCs, have the ability to self-renew, but they possess the potential to differentiate into other specialized cells when placed in appropriate culture conditions. 62 For the purpose of treating cartilage defects, MSCs need to be differentiated toward chondrongenic lineage of cells and more specifically toward the formation of hyaline Type 2 cartilage. Aside from MSC differentiation properties, they also have a trophic activity and secrete bioactive factors that have a protective immunoregulatory effect on the local tissue environment. Their antiinflammatory and differentiation properties make MSCs good contenders for a possible tissue repair modality in osteoarthritis.
63
Both synovial membrane-derived, bone marrow-derived MSC (BMSC), and adipose-derived stem cells (ASC) from adult tissues have the potential to form a hyaline-like cartilage matrix, with the latter being a more abundant and minimally morbid source (hildner). For example, recent studies suggest that the infrapatellar fat pad of adult knees is a good source of cells that can be induced to differentiate into chondrocytes that synthesize cartilage matrix molecules.
63 BMSC and ASC require a different growth factor treatment to differentiate into the sought after material. Aggrecan upregulation in ASC is seen when treated with bone morphogenetic protein 6 (BMP-6), while in BMSC, TGF-β3 is needed instead. In addition, several studies have concluded that BMSC are more easily differentiated toward the chondrogenic lineage than ASC.
62,63
Park et al showed that MSCs from both bone marrow and periosteum formed hyaline cartilaginous tissue when transplanted into cartilage defects in rats. This study also demonstrated that MSCs derived from bone marrow was superior to adipose-derived MSCs in forming hyaline cartilage in vivo. 64 Bone marrow, synovium, adipose tissue, and muscle of adult rabbits have also been studied to compare their in vivo chondrogenic potential. Results have shown that the potential of synovial and bone marrow MSCs to repair cartilage defects is higher than those from skeletal muscle and adipose tissue, and they produced more cartilage matrix than the other cells in the cartilage defects. More specifically, the MSCs taken from the synovial tissue had the greatest proliferation potential.
65
Wakitani et al performed a clinical study using bone marrow-derived MSCs re-suspended in a collagen type I gel and transplanted with autologous periosteal flap. This cellcontaining scaffold was placed into osteoarthritic cartilage defects in the patients' medial femoral condyles. This was compared with patients who were transplanted with a cellfree scaffold in a similar defect. 66 Results showed that the celltreated groups clinical scores were not significantly different 64 months after transplantation compared with the control group. In this situation, longer observation might be required and/or MSC transplantation may not be as effective in an osteoarthritic knee environment. 66 However, both the arthroscopic and histological scores were better in the group treated with the MSC transplant. 66 In addition, three future case reports from the same group did report that the clinical symptoms in the patients with the MSC-transplant had improved.
In another clinical study, human bone marrow MSCs were used to treat a 20 Â 30 mm full thickness cartilage medial femoral condyle defect in a 31-year-old male athlete. Bone marrow was aspirated from the patient 4 weeks before surgery and the cells were expanded in culture and then covered with an autologous periosteal flap once transferred to the defect. In a 7-month postsurgical evaluation, the defect was covered with a hyaline-like type of cartilage tissue. This smooth tissue also stained positively with Safranin-O. Clinically, the patient's symptoms involved significantly and was able to return to full physical activity level with no pain or complications.
65,67
Conclusions
Since articular cartilage defects have limited intrinsic regenerative properties, there is an interest in providing nontraditional modifications to injured articular cartilage in patients. To explore methods to repair articular cartilage, transplantation of various progenitor cells other than chondrocytes is under investigation with renewed vigor to provide additional solutions to articular cartilage repair. Recent basic science and clinical research has initiated a paradigm shift in our understanding of the role of cytokines, growth factors, and stem cells in potential cartilage repair. Although results have been promising in animal studies, extensive human clinical studies are necessary to ascertain the benefit of the use of growth factors or blood-derived products to repair articular cartilage defects.
